Cesca Therapeutics to Present at the 2017 Cell & Gene Meeting on the Mesa
27 September 2017 - 9:00PM
Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated
cell processing and point-of-care, autologous cell-based therapies,
today announced that Dalip Sethi, Ph.D., senior director of
research and development, will participate in the 2017 Cell &
Gene Meeting on the Mesa, which is being held October 4-6, 2017 at
the Estancia La Jolla Hotel in La Jolla, California. Dr. Sethi will
present an overview of Cesca Therapeutics’ autologous cell
processing capabilities on Wednesday, October 4 at 11:30am in La
Jolla Ballroom 2.
For more information, please visit
http://www.meetingonthemesa.com.
About the Cell & Gene Meeting on the
MesaThe Cell & Gene Meeting on the Mesa is a three-day
conference combining discussions between key opinion leaders,
senior executives and top academic researchers in the field of
regenerative medicine. The program also includes 60+ presentations
by the field’s most promising companies and poster abstracts by
leading scientists from around the globe.
About Cesca Therapeutics Inc.Cesca is a leading
regenerative medicine company that develops, commercializes and
markets a range of automated technologies for cell-based
therapeutics. Its device division, ThermoGenesis, provides a full
suite of solutions for automated clinical biobanking, point-of-care
applications, and automation for immuno-oncology. Cesca is also
leveraging its proprietary AutoXpress® technology platform to
develop autologous stem cell-based therapies that address
significant unmet needs in the vascular, cardiology and orthopedic
markets.
Forward-Looking StatementThe statements
contained herein may include statements of future expectations and
other forward-looking statements that are based on management’s
current views and assumptions and involve known and unknown risks
and uncertainties that could cause actual results, performance or
events to differ materially from those expressed or implied in such
statements. A more complete description of risks that could cause
actual events to differ from the outcomes predicted by Cesca
Therapeutics' forward-looking statements is set forth under the
caption "Risk Factors" in Cesca Therapeutics’ annual report on Form
10-K and other reports it files with the Securities and Exchange
Commission from time to time, and you should consider each of those
factors when evaluating the forward-looking statements.
Company Contact: Cesca Therapeutics
Inc.Wendy Samford916-858-5191ir@cescatherapeutics.com
Investor Contact: Rx CommunicationsPaula
Schwartz917-322-2216pschwartz@rxir.com
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Apr 2024 to May 2024
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Cesca Therapeutics Inc (NASDAQ): 0 recent articles
More News Articles